Core Insights - The article compares two medical services stocks, Pediatrix Medical Group (MD) and Revvity (RVTY), to determine which offers better value for investors [1] Valuation Metrics - Pediatrix Medical Group has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Revvity has a Zacks Rank of 3 (Hold) [3] - MD has a forward P/E ratio of 8.04, significantly lower than RVTY's forward P/E of 25.15, suggesting MD is undervalued [5] - The PEG ratio for MD is 1.81, compared to RVTY's 2.83, indicating MD's expected earnings growth is more favorable [5] - MD's P/B ratio is 1.17, while RVTY's P/B ratio is 1.87, further supporting MD's valuation as more attractive [6] - Based on these metrics, MD receives a Value grade of A, while RVTY is rated C, highlighting MD's superior value proposition [6] Earnings Outlook - MD is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model [7]

Revenue Details - Revvity operates under two segments: Life Sciences and Diagnostics [1] Financial Performance - Adjusted operating income for Revvity was $112.4 million, reflecting a 12% decrease from the prior-year quarter [2] - Revenues for Revvity totaled $691.7 million, down 2% year over year and 1% organically, missing the Zacks Consensus Estimate by 0.4% [16] - Revenues from the Life Sciences segment were $378 million, up 1.4% year over year, with an organic increase of 3% [8] - Revenues from the Diagnostics segment were $313.8 million, indicating a 6.7% decrease from the year-ago quarter, with a 6% organic decline [23] - Adjusted operating income for the Diagnostics segment was $97.9 million, up 14.9% from the year-ago quarter [24] - Selling, general and administrative expenses totaled $251.7 million, down 5.8% year over year, while research and development expenses were $48.1 million, down 15.9% [17] Cash Position - At the end of Q2 2024, Revvity had cash and cash equivalents of $1.95 billion, an increase from $1.70 billion at the end of the prior quarter [4] - Net cash provided by operating activities was $158.6 million, compared to a net cash used of $135.3 million in the year-ago quarter [18] 2024 Guidance - For 2024, Revvity expects adjusted EPS in the range of $4.70-$4.80 and revenues between $2.77-$2.79 billion, with the Zacks Consensus Estimate for EPS at $4.64 and revenues at $2.80 billion [12] Market Performance - Revvity's shares have gained 3.6% over the past six months, compared to the industry's growth of 6.7% and the S&P 500 Index's increase of 10.9% [19] - Revvity currently holds a Zacks Rank of 4 (Sell) [13]

Core Insights - Revvity reported second-quarter profit and sales that exceeded estimates due to higher demand for its diagnostic products [1][2] - The company raised its full-year adjusted EPS guidance, indicating positive future expectations [4] Financial Performance - Adjusted operating earnings per share (EPS) for the second quarter were $1.22, surpassing the average analyst estimate by $0.10 [2] - Revenue for the second quarter was $691.7 million, a decline of 2.5% year-over-year, but still above forecasts [2] - Revenue in the Diagnostics segment increased by 1.4% to $378.0 million, while the Life Sciences segment saw a decline of 6.7% to $313.8 million [3] Future Outlook - The adjusted EPS outlook for 2024 was raised to a range of $4.70 to $4.80 from the previous guidance of $4.55 to $4.75 [4] - Revenue outlook was narrowed to between $2.77 billion and $2.79 billion, compared to the earlier range of $2.76 billion to $2.82 billion [4] Market Reaction - Revvity shares rose by 3.5% to $119.18, reaching their highest level in almost a year [5]

Revvity, Inc. (NYSE:RVTY) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan ...

Revvity (RVTY) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the ear ...

FOR IMMEDIATE RELEASE July 29, 2024 • Revenue of $692 million; (2)% reported growth; (1)% organic growth • GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 • Raises full year 2024 adjusted EPS guidance Adjusted earnings per share from continuing operations for the quarter was $1.22, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. Adjusted operating income was $199 million, as ...

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Revvity? Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- ...

This maker of scientific instruments has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 6.48%. With this earnings history in mind, recent estimates have been moving higher for Revvity. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. ...

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities Revvity's end-to-end workflow includes ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its first-quarter 2024 performance and focus on artificial intelligence (AI), also looks promising. Headwinds resulting from foreign exchange volatility and integration risks are major downsides. This Zacks Rank #3 (Hold) company's shares have risen 0.4% year to date compared with 2.4% growth of the industry.The S&P 500 has increased 11.6% during the same time frame. The reno ...